--- title: "CytoSorbents | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286310038.md" datetime: "2026-05-13T20:11:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286310038.md) - [en](https://longbridge.com/en/news/286310038.md) - [zh-HK](https://longbridge.com/zh-HK/news/286310038.md) --- # CytoSorbents | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 8.864 M Revenue: As of FY2026 Q1, the actual value is USD 8.864 M, missing the estimate of USD 9.363 M. EPS: As of FY2026 Q1, the actual value is USD -0.08, missing the estimate of USD -0.055. EBIT: As of FY2026 Q1, the actual value is USD -4.272 M. ### First Quarter 2026 Financial Results #### Revenue Revenue was $8.9 million, representing a 2% increase from $8.7 million in the prior year . #### Gross Margin Gross margin for the quarter was 69%, a decrease from 71% in Q1 2025, primarily due to intentionally reduced production volumes aimed at lowering inventory levels and improving working capital . #### Operating Profit/Loss Operating loss was $3.0 million, an improvement compared to an operating loss of $3.9 million in Q1 2025, benefiting from a strategic workforce and cost reduction initiative implemented in Q4 2025 . #### Net Income/Loss Net loss was $5.1 million, or -$0.08 per share, an increase from a net loss of $1.5 million, or -$0.02 per share, in Q1 2025, mainly attributed to the non-cash impact of changes in foreign currency transactions year-over-year . Adjusted net loss, excluding non-cash changes in foreign currency transactions and non-cash stock compensation, was $3.4 million, or -$0.05 per share, an improvement from an adjusted net loss of $3.7 million, or -$0.06 per share, in Q1 2025 . #### Adjusted EBITDA Adjusted EBITDA loss, excluding non-cash changes in foreign currency transactions and non-cash stock compensation, was $2.2 million, an improvement from a loss of $2.7 million in Q1 2025 . #### Cash and Cash Equivalents Total cash, cash equivalents, and restricted cash were approximately $6.4 million as of March 31, 2026, down from $7.8 million as of December 31, 2025 . #### Cash Burn Total cash burn in the quarter, excluding $0.3 million in restructuring-related payments, was approximately $1.1 million . #### Operating Cash Flow Net cash used in operating activities was -$1,162 thousand for the three months ended March 31, 2026, compared to -$3,466 thousand for the same period in 2025 . #### Investing Activities Net cash used in investing activities was -$46 thousand for the three months ended March 31, 2026, compared to -$47 thousand for the same period in 2025 . #### Financing Activities Net cash provided by financing activities was $0 for the three months ended March 31, 2026, compared to $6,831 thousand for the same period in 2025 . ### Operational Highlights Direct sales territories outside of Germany experienced a 13% growth in sales . Distributor sales were flat year-over-year, impacted by approximately $500,000 in delayed orders from parts of the Middle East and neighboring regions due to geopolitical and economic instability . Cytosorbents Corporation is evaluating options for additional mechanistic data for the DrugSorb-ATR De Novo application and anticipates submitting a new application in late 2026 or early 2027 . The company plans to submit a separate pre-submission request to the FDA within 30 days to review data for the Direct Oral Anticoagulants (DOAC) indication for DrugSorb-ATR . ### Outlook / Guidance Cytosorbents Corporation aims to selectively expand its commercial team in Germany and continue operational improvements and cost reductions, with the goal of achieving operating cash flow breakeven in the second half of 2026 . The company is also actively evaluating a potential parallel path for DrugSorb-ATR focused on DOACs, which could significantly expand the U.S. market opportunity . ### Related Stocks - [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md) ## Related News & Research - [CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News](https://longbridge.com/en/news/286308377.md) - [CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 | CTSO Stock News](https://longbridge.com/en/news/279801870.md) - [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md) - [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md) - [CytoSorbents 2025 revenue rises, net loss narrows](https://longbridge.com/en/news/280524501.md)